Forward P/S Multiple: IRIDEX Corp (IRIX)

IRIDEX - graphic logo of issuer IRIX

IRIDEX Corporation dominates the ophthalmology sector thanks to MicroPulse, which ensures safe treatment for the retina and glaucoma. Checking the expected P/S ratio on GURU.Markets, we see that 0.20 serves as the base value for this parameter. Distribution growth is supported by training physicians to operate the Cyclo G6. High regulatory barriers and patent protection securely safeguard the brand's position in the global market.

IRIDEX - IRIX Market Cap to Projected Revenue (period 07/04/2022 - 11/14/2026)

Summary analytical data breakdowns for IRIDEX (IRIX)

- market price and analyst price targets:
Price Chart IRIDEX Corporation|IRIX - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization IRIDEX Corporation|IRIX - Total Enterprise Value
- issuer book value statistics:
Book Value per Share IRIDEX|IRIX - Accounting Capitalization|Market Capitalization to Book Value Ratio iridex.com|IRIX - Company Total Asset Base
- debt and liquidity data:
Total Debt to Capital IRIDEX Corporation|IRIX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital IRIDEX Corp|IRIX - Company Aggregate Debts|Debt to Book Capitalization Ratio IRIDEX Corporation|IRIX - Company Long-Term Debt|Company Current Liabilities IRIDEX|Quick Ratio iridex.com
- financial results and valuation multiples details:
IRIX - Company Net Income|Expected Profit IRIDEX Corporation|IRIX - Market Cap to Net Income Ratio|Projected Price to Earnings IRIDEX Corp|IRIX - PEG Multiple|EV/EBITDA Multiple IRIDEX Corp.|IRIX - Operating income before deduction of amortization|Earnings per share for the last twelve months IRIDEX|IRIX - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months iridex.com|IRIX - Net earnings per share growth this year|Earnings growth forecast for next year IRIDEX Corporation
- sales and revenue indicators:
IRIX - Company Total Revenue|Company Projected Revenue iridex.com|IRIX - Market Cap to Revenue Ratio|Forward Price-to-Revenue Multiple IRIDEX Corporation
Fundamental company analysis:IRIX (iridex.com)
Product sample of iridex.com

To assess the financial stability of IRIDEX Corporation (IRIX), investors must analyze the forward P/S ratio, which compares current market capitalization to expected revenue, reflecting the market's real-time assessment of business prospects. Amidst saturation in the laser equipment market, the forward P/S trend helps determine whether the company's valuation adequately accounts for the steady cash flow generated by the sale of microsurgery consumables.

Who IRIDEX Corporation competes with

Price-to-Projected Revenue Ratio Dexcom CGM DXCM|Penumbra Corp (PEN) - Market Cap to Future Revenue Ratio|Novanta Inc - Forward P/S Multiple|HAE (Haemonetics Corporation) - Market Cap to Projected Revenue|INSP: Forward P/S Multiple|Market Cap to Projected Revenue PRCT|CNMD (CONMED Inc.) - Forward P/S Multiple|Pulse Corp (PLSE) - Market Cap to Expected Sales Ratio|Forward P/S Multiple INMD|Forward P/S Multiple picardmedical.com (PMI)|Forward P/S Multiple SRDX (surmodics.com)|Forward P/S Multiple Senseonics Holdings, Inc. SENS|NPCE - Price-to-Projected Revenue Ratio|TCMD: Price-to-Projected Revenue Ratio|SNWV (Sanuwave Health Inc) - Forward Price-to-Revenue Multiple|Projected Price to Revenue Outset Medical OM|ELMD (SmartVest) - Forward P/S Multiple|Market Cap to Future Revenue Ratio LENSAR Inc. LNSR|Price-to-Projected Revenue Ratio AVITA Medical Inc. (RCEL)|Profound Medical Corporation (PROF) - Projected Price to Revenue|Baird Medical Investment Holdings - Forward Price-to-Revenue Multiple|Forward P/S Multiple EDAP Medical EDAP|Apyx Medical Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio IceCure Medical ICCM|Pulmonx (LUNG) - Price-to-Projected Revenue Ratio|Future Price to Revenue TELA (TELA Bio Corp)|Price-to-Projected Revenue Ratio cytosorbents.com|Forward Price-to-Revenue Multiple Sensus Healthcare, Inc. (SRTS)|Forward P/S Multiple ZYXI|ECOR - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio vicarioussurgical.com RBOT|IINN: Market Cap to Projected Revenue|ICU - Price-to-Projected Revenue Ratio|ibs.inc - Price to Expected Revenue Ratio|XAIR: Forward P/S Multiple|Future Price to Revenue PFSA (Profusa Inc.)|Forward Price-to-Revenue Multiple SSKN|Price-to-Projected Revenue Ratio GCTK|Price-to-Projected Revenue Ratio NanoVibronix (NAOV)|Venus Concept - Market Cap to Projected Revenue|Forward P/S Multiple NUWE (Nuwellis Corp)|Forward Price to Sales AEMD|ASXC - Price-to-Projected Revenue Ratio|Projected Price to Revenue Avinger, Inc (AVGR)|BSGM: Forward P/S Multiple|Cutera (CUTR) - Forward P/S Multiple|KNW (Know Labs) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Inari Medical (NARI)|Price-to-Projected Revenue Ratio nevro.com (NVRO)|RSLS (ReShape Lifesciences, Inc.) - Forward Price to Sales|Forward P/S Multiple SILK (Silk Road Medical)